CVS Health Corp (NYSE:CVS) stock fell 2.54% (As on August 3, 11:10:20 AM UTC-4, Source: Google Finance) after the company  said it began cutting jobs and had shut its clinical trials services as part of a plan to rein in costs as the company gears up for a tough environment for its health insurance business next year. The company, which includes one of the largest U.S. pharmacy benefit managers and the Aetna health insurer along with its chain of retail pharmacies, bought primary-care provider Oak Street Health and home healthcare services firm Signify Health in the past few months as it aims to play a greater role in patient care. High integration costs from the deals, as well as increasing medical costs due to higher demand for elective surgeries, are expected to pressure its earnings this year and the next. Health insurers are also expected to receive lower payouts for government-backed Medicare Advantage plans for Americans aged 65 and older. CVS recorded a $496 million restructuring charge during the quarter and said it would eliminate 5,000 non-customer-facing jobs. It expects those efforts to help it achieve cost savings of $700 million to $800 million through next year.

CVS in the second quarter of FY 23 has reported the adjusted earnings per share of $2.21, beating the analysts’ estimates for the adjusted earnings per share of $2.13. The company had reported the adjusted revenue growth of 10.3 percent to $88.92 billion in the second quarter of FY 23, beating the analysts’ estimates for revenue of $86.41 billion. Adjusted operating income decreased 10.4% primarily driven by declines in the Health Care Benefits and Pharmacy & Consumer Wellness segments, partially offset by increases in the Health Services segment. Interest expense increased $103 million or 17.7%, due to higher debt in the three months ended June 30, 2023 to fund the acquisitions of Signify Health, Inc. and Oak Street Health, Inc.

CVS also trimmed its 2024 profit forecast to $8.50 to $8.70 per share from its prior view of about $9, and withdrew its 2025 adjusted earnings forecast of $10 per share.

The company maintained its 2023 adjusted profit forecast at $8.50 to $8.70 per share, but said it expects its medical benefit ratio, to come in at the higher end of its outlook of 84.7% plus or minus 50 basis points.